Lung Cancer - Non-Small Cell News
Standard Dose of Radiation Therapy Outperforms Higher Dose for Advanced Non-Small Cell Lung Cancer (June 12, 2013)In a phase III clinical trial, a standard dose of radiation therapy was more effective than a higher dose for the treatment of stage III non-small cell lung cancer (NSCLC). These results will be presented at the 49th Annual Meeting of the American Society... Continue Reading
Ganetespib Promising for Advanced Lung Cancer (June 6, 2013)In a Phase II clinical trial, second-line treatment with a combination of chemotherapy and the investigational drug ganetespib improved overall survival among patients with advanced lung adenocarcinoma. These results were presented at the 2013 Annual... Continue Reading
Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading
Screening Could Reduce Lung Cancer Mortality (April 24, 2013)Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers could potentially avert approximately 12,000 lung cancer deaths each year in the United States, according to the results of a study... Continue Reading
Cancer Deaths on the Decline (February 11, 2013)Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading
Xgeva Improves Survival Over Zometa in Advanced Lung Cancer (November 28, 2012)Patients with advanced lung cancer experienced modest improvement in survival when they received bone-targeted therapy with Xgeva® (denosumab) instead of Zometa® (zoledronic acid), according to the results of a study published in the Journal of Thoracic... Continue Reading
Stereotactic Body Radiation Improves Lung Cancer Survival (November 9, 2012)Stereotactic body radiation for early-stage, inoperable non-small cell lung cancer yields high overall survival rates and low toxicity compared to conventional radiotherapy, according to the results of a study presented at the annual meeting of the American... Continue Reading
Hormone Replacement Therapy in Newly Menopausal Women May Carry More Benefit Than Risk (October 26, 2012)Hormone replacement therapy for newly menopausal women may not be as risky as once believed, according to the results of a study presented at the 23rd annual meeting of the North American Menopause Society in Orlando, Florida in October 2012.[1] In fact,... Continue Reading
Xalkori Superior to Standard Chemotherapy in ALK-Positive Lung Cancer (October 4, 2012)The targeted therapy Xalkori® (crizotinib) is superior to standard chemotherapy for the treatment of patients with advanced, ALK-positive non-small cell lung cancer, according to the results of a phase III trial presented at the ESMO 2012 Congress of... Continue Reading
Genetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer (September 19, 2012)Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study published in Nature. The discovery could lead to new targeted... Continue Reading
Latest Lung Cancer - Non-Small Cell News By Stage
Recurrent Lung Cancer - Non-Small Cell
Xgeva Improves Survival Over Zometa in Advanced Lung Cancer (November 28, 2012)
Patients with advanced lung cancer experienced modest improvement in survival when they received bone-targeted therapy with Xgeva® (denosumab) instead of Zometa® (zoledronic acid), according to the results of a study published in the Journal of Thoracic... Continue Reading
Xalkori Superior to Standard Chemotherapy in ALK-Positive Lung Cancer (October 4, 2012)The targeted therapy Xalkori® (crizotinib) is superior to standard chemotherapy for the treatment of patients with advanced, ALK-positive non-small cell lung cancer, according to the results of a phase III trial presented at the ESMO 2012 Congress of... Continue Reading
Genetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer (September 19, 2012)Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study published in Nature. The discovery could lead to new targeted... Continue Reading
Two Studies Show Promise in Second-Line Treatments for NSCLC (August 14, 2012)Two studies presented at the 2012 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois shed new light on the best way to treat non-small cell lung cancer (NSCLC)—one indicating that chemotherapy may be superior to... Continue Reading
PD-1 Targeted Immune Therapy Shows Promising Activity (June 11, 2012)The investigational drug BMS-936558 caused tumor shrinkage in nearly 25 percent of patients with advanced melanoma, kidney cancer and non-small cell lung cancer (NSCLC), according to the results of a phase I study presented at the 2012 annual meeting... Continue Reading
More Recurrent Lung Cancer - Non-Small CellScreening/Prevention Lung Cancer - Non-Small Cell
Screening Could Reduce Lung Cancer Mortality (April 24, 2013)
Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers could potentially avert approximately 12,000 lung cancer deaths each year in the United States, according to the results of a study... Continue Reading
Hormone Replacement Therapy in Newly Menopausal Women May Carry More Benefit Than Risk (October 26, 2012)Hormone replacement therapy for newly menopausal women may not be as risky as once believed, according to the results of a study presented at the 23rd annual meeting of the North American Menopause Society in Orlando, Florida in October 2012.[1] In fact,... Continue Reading
Female Lung Cancer Deaths on the Rise in Some Areas (July 3, 2012)Lung cancer deaths are on the rise among young and middle-aged white women, mainly in the South and the Midwest, according to a study published in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer death among both men and... Continue Reading
Diesel Exhaust Linked to Lung Cancer (June 26, 2012)Diesel exhaust is associated with an increased risk of lung cancer, according to a press release issued by the World Health Organization (WHO).[1] The announcement came after a group of international experts gathered for a weeklong meeting to review the... Continue Reading
New Lung Cancer Screening Guidelines (May 25, 2012)New lung cancer screening guidelines recommend annual CT scans only for a select group of people—those aged 55 to 74 who are current or former smokers. The guidelines are the result of a systematic review by an expert panel from several medical groups... Continue Reading
More Screening/Prevention Lung Cancer - Non-Small CellStages I-IIIA Lung Cancer - Non-Small Cell
Standard Dose of Radiation Therapy Outperforms Higher Dose for Advanced Non-Small Cell Lung Cancer (June 12, 2013)
In a phase III clinical trial, a standard dose of radiation therapy was more effective than a higher dose for the treatment of stage III non-small cell lung cancer (NSCLC). These results will be presented at the 49th Annual Meeting of the American Society... Continue Reading
Stereotactic Body Radiation Improves Lung Cancer Survival (November 9, 2012)Stereotactic body radiation for early-stage, inoperable non-small cell lung cancer yields high overall survival rates and low toxicity compared to conventional radiotherapy, according to the results of a study presented at the annual meeting of the American... Continue Reading
Genetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer (September 19, 2012)Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study published in Nature. The discovery could lead to new targeted... Continue Reading
Higher Radiation Dose Does Not Benefit Lung Cancer Patients (October 13, 2011)Among patients with Stage III non-small cell lung cancer, treatment with a higher dose of radiation therapy does not result in better overall survival than a standard dose of radiation therapy. These results were presented at the 53rd Annual Meeting of... Continue Reading
Elderly, Minorities and Women Under-represented in Lung Cancer Clinical Trials (August 25, 2011)Compared with the demographics of lung cancer in the United States, the elderly, minorities, and women remain vastly under-represented in lung cancer clinical trials. These results were presented at the 14th World Conference on Lung Cancer. Clinical trials... Continue Reading
More Stages I-IIIA Lung Cancer - Non-Small CellStages IIIB-IV Lung Cancer - Non-Small Cell
Standard Dose of Radiation Therapy Outperforms Higher Dose for Advanced Non-Small Cell Lung Cancer (June 12, 2013)
In a phase III clinical trial, a standard dose of radiation therapy was more effective than a higher dose for the treatment of stage III non-small cell lung cancer (NSCLC). These results will be presented at the 49th Annual Meeting of the American Society... Continue Reading
Ganetespib Promising for Advanced Lung Cancer (June 6, 2013)In a Phase II clinical trial, second-line treatment with a combination of chemotherapy and the investigational drug ganetespib improved overall survival among patients with advanced lung adenocarcinoma. These results were presented at the 2013 Annual... Continue Reading
Xgeva Improves Survival Over Zometa in Advanced Lung Cancer (November 28, 2012)Patients with advanced lung cancer experienced modest improvement in survival when they received bone-targeted therapy with Xgeva® (denosumab) instead of Zometa® (zoledronic acid), according to the results of a study published in the Journal of Thoracic... Continue Reading
Xalkori Superior to Standard Chemotherapy in ALK-Positive Lung Cancer (October 4, 2012)The targeted therapy Xalkori® (crizotinib) is superior to standard chemotherapy for the treatment of patients with advanced, ALK-positive non-small cell lung cancer, according to the results of a phase III trial presented at the ESMO 2012 Congress of... Continue Reading
Genetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer (September 19, 2012)Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study published in Nature. The discovery could lead to new targeted... Continue Reading
More Stages IIIB-IV Lung Cancer - Non-Small Cell